NON PROFIT
1 min.Read

ACC Cardio-oncology Course Aims to Advance Cardiovascular Care of Cancer Patients, Survivors

January 21, 2021

ACC Cardio-oncology Course: The American College of Cardiology will host the annual Advancing the Cardiovascular Care of the Oncology Patient Virtual course with live sessions on Feb. 5-6, 2021, and on demand content. The course will feature cardiology and oncology experts providing clinically relevant, best practice strategies for a multidisciplinary team regarding the assessment, diagnosis and management of cardiovascular concerns for cancer patients, as well as those requiring survivorship care.

ACC Cardio-oncology Course co-directors Ana Barac, MD, Ph.D., FACC, and Bonnie Ky, MD, MSCE, FACC, have invited respected experts in the field to create a course covering relevant and required content for both the novice and advanced practitioner. The conference aims to provide participants with the tools needed to improve patient care in their everyday practice in this rapidly evolving field through describing the evolving advances in immunotherapy and the associated cardiotoxicity; defining cardiovascular complications in cancer patients that are specific to coronary disease, vascular disease and bleeding; applying evidence-based strategies for short- and long-term surveillance; and establishing interprofessional cardio-oncology care teams and a framework to improve overall cardiovascular care of cancer patients and survivors.

Sessions Include:

  • Immune Therapy and Cardiovascular Risk
  • Adult and Pediatric Cancer Survivorship: Management of Modifiable Cardiovascular Risk Factors
  • All About Amyloidosis

The course will also feature on-demand content available beginning on Monday, January 25, 2021.

Posters

The following abstracts are a selection of the posters being presented. All ACC Advancing the Cardiovascular Care of the Oncology Patient abstracts are embargoed until Monday, Jan. 25, 2021 at 8 a.m. ET.

  • Cardiovascular Outcomes Associated with Chemotherapy and Targeted Therapies in Adolescent and Young Adult Cancer Survivors
  • Cardiovascular Risk Factors and Comorbidities in Male Breast Cancer Patients (press release available)
  • Risk of Cardiotoxicity with Dual Human Epidermal Receptor (HER2) Targeted Therapies in Breast Cancer
  • The Association of Physical Activity, Cardiac and Patient-Reported Outcomes in HER2+ Breast Cancer Survivors During Therapy
SourceAmerican College of Cardiology

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

0
Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

0
Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

0
Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

0
The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

0
“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device news and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York
United States
Phone Number: 1.561.316.3330